Nanobiotix (NBTX) Operating Leases (2021 - 2023)
Nanobiotix's (NBTX) quarterly Operating Leases came in at $5.0 million in Q2 2023, down 13.56% year-on-year from $5.8 million in Q2 2022, and down 13.56% quarter-over-quarter from $5.8 million in Q2 2022.
Nanobiotix (NBTX) Operating Leases (2021 - 2023) Analysis & Trends
Nanobiotix's Operating Leases history runs 3 years deep, the most recent figure standing at $5.0 million for Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Alnylam Pharmaceuticals | 35.71 Bn | 32.70 Bn | 959.66 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 4.97 Mn |
| Jun 30, 2022 | 5.75 Mn |
| Jun 30, 2021 | 6.01 Mn |